We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Stroli – the shopping trolley reimagined for modern needs. The shopping trolley, often associated with a particular image, is an untapped category ready for innovation. The market is flooded with generic, budget-friendly options that lack charm, with the exception of Rolser, which is pricier and claims the green niche. Stroli steps in as the go-to brand, offering a unique approach, positioning, voice, and eco-friendly credentials. Say goodbye to sore hands and plastic bags – Stroli makes shopping a pleasure with its high-quality, stylish trolley bags designed to enhance your convenience and style
days to go: Extended investment: Withheld
First Natural Brands is the owner of Tisserand Aromatherapy, one of the leading self-governing players in UK’s essential oil industry. It offers a variety of affordable organic and quality accredited products which consumers can relish as part of their daily lifestyle. Tisserand Aromatherapy is experiencing a growing interest among media, retail and consumers. Since 2007, the company’s sales have increased from £1.7mn to £6mn, owing to Robin Russell (CEO & Chairman) for bringing Tisserand into the mainstream market with a value for money proposition. Further investment will allow the company to expand its production capacity.
days to go: Expired investment: £325,660
Founded in 2012, Holly and Beau is an award-winning kids-wear brand which offers a unique collection of colour changing rainwear. The company sells its products directly through its website and via distributors in the UK, the US, Europe and South Korea. Holly and Beau is in the process of patenting its technology, which will enable it to develop a unique product range of rainwear and skiwear. Moreover, the company has successfully maintained an average revenue growth of 80%-100% YOY.
days to go: Expired investment: £218,570
BLOK is a multi-disciplinary studio and digital fitness platform. The company's first site in Clapton, Hackney opened in Q1 of 2016, followed by Shoreditch in 2018, and Manchester in 2019. In May 2020, BLOK launched BLOKtv. This launch led to nearly 2,000 people joining BLOK's classes each week with more customers joining in from 134 countries. The digital fitness market has experienced an annual growth of 33% since 2017, and BLOK aims to be the market leader in this segment. The company has hosted global stars such as Anthony Joshua, Jourdan Dunn, Kayla Itsines, Conor Benn and Alicia Vikander. BLOK's studios have also featured on programmes such as 'Britain's Next Top Model' and 'Made in Chelsea'. The company raised over £891,000 from 571 investors on Crowdcube in 2018. It will use the investment to accelerate the growth of BLOKtv and further build its digital community.
days to go: Expired investment: £536,163
By combining fitness with fashion, art and design, BLOK has become a major competitor of boutique class-based gyms within London. BLOK has appeared on Britain's Next Top Model, as well as working with global stars including Anthony Joshua and Jordan Dunn.

Pitch Rated

60%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £891,790
Qure are an affordable and convenient on-demand healthcare service providing a doctor to users doors within 2 hours, 24/7. The hassle-free healthcare connects individuals with highly-experienced medical practitioners in the local area. 
days to go: Expired investment: £720,000
Arca is helping to build the market for property market risk transfer by dealing in derivatives for domestic and commercial properties. Nick Ruddell has held senior roles for the last 30 years with banks and big interdealer brokers.
days to go: Expired investment: £676,500
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph